Tumor News and Research

RSS

Researchers identify new potential drug target that may block SARS-CoV-2 infection

In the quest for new treatments for COVID-19, a team led by researchers at UC San Francisco has identified a new potential drug target that may block infection by SARS-CoV-2. The protein, called BRD2, regulates the ACE2 receptor, which the novel coronavirus relies on to gain entry to its host's cells.

17 Jan 2022

Moffitt researchers unravel the role of B cells in endometrial cancer

Endometrial cancer is the most common cancer of the female reproductive system. Patients who have active immune responses against cancer cells tend to have better outcomes, but much of what is known focuses on only one type of immune cell called T cells.

13 Jan 2022

Targeting MAPK4 in triple-negative breast cancer may lead to improved treatments

Scientific evidence supporting the involvement of the enzyme MAPK4 in cancer growth and resistance to certain therapies has been growing quickly.

12 Jan 2022

Researchers reveal molecular and cellular mechanisms that lead to tertiary lymphoid structures formation

Tertiary lymphoid structures are formations that occur outside of the lymphatic system. They contain immune cells and are similar in structure and function to lymph nodes and other lymphoid structures.

12 Jan 2022

Research provides novel insights on cancer immunotherapy

UC San Francisco researchers have defined 12 classes of “immune archetypes” to identify cancer tumors based on data from over 300 patient tumors.

10 Jan 2022

Scientists use fruit fly embryos to study immune cell invasion

To fight infections and heal injuries, immune cells need to enter tissue. They also need to invade tumors to fight them from within.

7 Jan 2022

Novel delivery system for genome editing in vascular endothelial cells developed

The laboratory of Youyang Zhao developed a novel nanoparticle to deliver genome editing technology, such as CRISPR/Cas9, to endothelial cells, which line blood vessel walls.

7 Jan 2022

A folic acid-like drug changes a DNA process within brain tumors

A folic acid-like drug, L-methylfolate, when administered alongside the standard therapy for patients with recurrent glioblastoma, changed aDNA process within their brain tumors, according to results from a phase 1 clinical trial.

6 Jan 2022

Researchers develop new CAR T cells that act as a "micropharmacy"

Immunotherapies called chimeric antigen receptor (CAR) T cells use genetically engineered versions of a patient's own immune cells to fight cancer. These treatments have energized cancer care, especially for people with certain types of blood cancers.

3 Jan 2022

Simple, marine-dwelling creature shines light on cancer resistance

A simple, marine-dwelling creature known as Trichoplax adhaerens has some remarkable properties. The organism can tolerate unusually high doses of radiation that would kill most other forms of life. T. adhaerens has another intriguing characteristic: the ability to resist cancer.

24 Dec 2021

Study uncovers mechanism that triggers cancer cell death

Scientists recently pinpointed the mechanism by which inhibitors of the ERK5 protein kinase diminish cancer cell proliferation and trigger their death.

23 Dec 2021

INTEGRA supports groundbreaking brain tumor research

INTEGRA Biosciences is proud to be supporting vital translational research into diffuse intrinsic ponsglioma (DIPG) – a rare childhood brain tumor – at the Ludwig Maximilian University of Munich (LMU) with a festive donation of 20,000 EUR.

From INTEGRA Biosciences 21 Dec 2021

Driving up the immune response at tumor site may help boost immunotherapy

Driving up the immune response at the site of a cancer tumor with nanotechnology may help enhance immunotherapy treatments in advanced stages of the disease, new research in mice suggests.

15 Dec 2021

Scientists find how cells remain dormant for years before awakening to create metastatic cancer

Mount Sinai researchers have solved a major mystery in cancer research: How cancer cells remain dormant for years after they leave a tumor and travel to other parts of the body, before awakening to create metastatic cancer.

14 Dec 2021

Study illustrates the concept of cool microscopy

Fluorescence light microscopy has the unique ability to observe cellular processes over a scale that bridges four orders of magnitude. Yet, its application to living cells is fundamentally limited by the very rapid and unceasing movement of molecules that define its living state.

14 Dec 2021

Genetic makeup of neuroblastoma shows marked spatial and temporal variability

Tumors are heterogeneous, which means that different parts of the same tumor can be genetically distinct. This phenomenon, known as intratumor heterogeneity, is steadily gaining in significance within the field of cancer research.

13 Dec 2021

Study helps identify how immune system cells identify and eradicate tumors

In the last 10 years, immunotherapy has been used to save the lives of several cancer patients with lung cancer.

13 Dec 2021

New classification method divides breast cancers into 12 distinct biological groups

Researchers at UNC Lineberger Comprehensive Cancer Center have taken a major step forward in melding two key methods for studying breast cancer: one by genetic analysis and the second by looking at the architecture of cells, or their pathology.

9 Dec 2021

Single-cell spatial analysis may provide information about neoadjuvant therapy for triple-negative breast cancer

A next-generation technology that allows the study of protein expression at the single-cell level and the location of the cells within the tumor microenvironment (TME) was feasible and provided information on the benefit of adding the immune checkpoint inhibitor atezolizumab (Tecentriq) to chemotherapy as neoadjuvant treatment for patients with early high-risk and locally advanced triple negative breast cancer (TNBC), according to results presented at the San Antonio Breast Cancer Symposium, held December 7-10, 2021.

8 Dec 2021

New strategy to improve the therapeutic efficacy of liver cancer immunotherapy

In recent years, tumor immunotherapy has emerged as a highly promising and much-touted oncological approach.